Axsome Therapeutics Inc

Director, In-House Global Health Economics & Outcomes Research (HEOR) - (East Coast Candidates)

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalIndustries

About PTC Therapeutics

PTC Therapeutics is a global commercial biopharmaceutical company. For over 25 years our team has been deeply committed to a unified purpose: Extending life’s moments for children and adults living with a rare disease.

At PTC, we cultivate an inclusive culture where everyone feels valued, respected, and empowered. We welcome candidates from all backgrounds to join our team, fostering a strong sense of belonging.

Job Description Summary

The Director of Global Health Economics & Outcomes Research Associate will participate in developing and implementing HEOR strategies that enhance the value proposition and supporting evidence of Sepiapterin, aiding its launch and post-launch phases. Additionally, the Director of HEOR is responsible for educating external customers about the clinical, economic, and humanistic impacts of PTC medicines and products to support formulary decision-making and improve population health. The Director of Global HEOR also ensures compliance with relevant regulatory requirements and company Standard Operating Procedures (SOPs) as appropriate.

Candidates must be East Coast Based

Responsibilities

  • Leads the execution of complex HEOR evidence generation strategies, including cost-effectiveness analysis, budget impact models, prospective and retrospective observational studies, ITCs, meta-analyses, systematic reviews, patient-reported outcomes measure development and validation, and other research necessary to support asset value.
  • Collaborate with the In-House HEOR Team and Market Access Team to implement HEOR scientific engagement strategies for external customers, such as Payers, PBMs, GPOs, and Clinical Pathway companies, within a specific territory or customer base. Coordinate with other PTC colleagues as needed to ensure compliance and achieve HEOR goals.
  • Serve as a conduit and resource for delivering scientific [clinical and healthcare economic information (HCEI)] to formulary decision-makers in accordance with PTC guidance.
  • Proactively communicate clinical and economic information related to PTC disease or PTC product to support formulary decisions and enhance patient care outcomes.
  • Respond to unsolicited customer requests for clinical and economic information related to Ipsen’s disease area or products to support formulary decisions and enhance patient outcomes.
  • Capture and communicate customer insights with internal Ipsen colleagues as appropriate, including identifying potential opportunities for research partnerships.
  • Utilizes best practices to deliver essential input for designing PTC observational research studies.
  • Collaborates with the medical communications teams on publication strategy and ensures that the dissemination of HEOR evidence is timely and maximizes impact.
  • Collaborates internally with Medical, Clinical, Market Access, Regulatory, and Biostats to develop and implement HEOR strategies, supporting PTC product therapeutic value.
  • Partners and works closely with Market Access to support the production of GVD and the Value Narrative.
  • Perform other tasks and assignments as needed and specified by management.

Qualifications

  • Advanced degree (PhD, PharmD, MS) in health economics, public health, or a related scientific discipline, along with a minimum of 7 years of cumulative experience in health economics and outcomes research, within a pharmaceutical, biotechnology, or related environment.
  • Strong track record of publication in peer-reviewed journals
  • Strong technical expertise in HEOR and can formulate and lead innovative research projects, ensuring conduct is scientifically rigorous and aligns with best HEOR practices.
  • Strong verbal and written communication skills, including presentation abilities to explain complex concepts and persuade others; comfortable adapting presentation style to various audiences.
  • Ability to apply knowledge of global health

Skills

Health Economics
Outcomes Research
HEOR
Cost-effectiveness analysis
Budget impact models
Observational studies
Meta-analyses
Systematic reviews
Patient-reported outcomes
Market Access
Scientific engagement
Formulary decision-making
Regulatory compliance
Standard Operating Procedures (SOPs)

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI